Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31408659 | 1.00 | KDM4E (1.00) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL3661768 | 0.91 | KDM4E (0.83) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL2900351 | 0.90 | KDM4E (0.82) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL2189622 | 0.89 | KDM4E (0.79) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL1012737 | 0.88 | KDM4E (0.78) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL6383531 | 0.88 | KDM4E (0.78) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL2857865 | 0.88 | KDM4E (0.78) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL11404760 | 0.88 | KDM4E (0.79) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL31716930 | 0.87 | KDM4E (0.76) | KDM4EGAAPOLBALDH1A1HSD17B10 | |
| SCHEMBL23520824 | 0.87 | KDM4E (0.77) | KDM4EGAAPOLBALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | ACADEMIA SINICA (TW) | 2026-04-21 | — | — | US | disclosed |
| EP-4692092-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | Aliad Biopharma (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4069252-B1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-115677601-B | Compound with anti-tumor activity and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119143671-B | Method for simply and conveniently synthesizing quinolinone derivative through one-pot method of carboinsertion reaction | 九洲药业(杭州)有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-3668863-B1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-4873232-A | ARTHRITIS AND AUTOIMMUNE DISEASES | SYNTEX (US) | 1989-10-10 | — | — | US | disclosed |
| US-4868117-A | ACTINOMADURA CULTURE | BRISTOL-MYERS COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4785010-A | AGING RESISTANCE OF HUMANS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| US-4708872-A | Antitumor antibiotic complex | BRISTOL-MEYERS COMPANY (US) | 1987-11-24 | — | — | US | disclosed |
| US-4675187-A | ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1987-06-23 | — | — | US | disclosed |
| US-4657893-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0147211-A2 | 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4337270-A | ANTIALLERGENS; ANTIANAPHYLACTIC AGENTS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1982-06-29 | — | — | US | disclosed |
| US-3976780-A | Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES L'ILE-DE-FRANCE (FR) | 1976-08-24 | — | — | US | disclosed |
| US-3954748-A | ANTIEMETICS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | KDM4E 4523/4885GAA 1454/4885POLB 904/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | KDM4E 3129/4885GAA 189/4885POLB 934/4885 |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | PDIA4, PDIA5, PDIA6 | KDM4E 2024/4885GAA 2125/4885POLB 4409/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | KDM4E 3061/4885GAA 4746/4885POLB 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.